anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Prostatic obstruction 5. Lower urinary tract symptoms
Provide patient population that should be included in the study
Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Benign prostatic hyperplasia 5. Lower urinary tract symptoms 6. Aged 65-79 years
Provide patient population that should be included in the study
Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Benign Prostatic Hypertrophy With Outflow Obstruction 5. Young Adult 19-24 years 6. Lower urinary tract symptoms 7. Aged 65-79 years
Provide patient population that should be included in the study
Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Transurethral Cystoscopy
Provide patient population that should be included in the study
Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Urolithiasis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Benign prostatic hyperplasia 5. Lower urinary tract symptoms
Provide patient population that should be included in the study
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Benign prostatic hyperplasia 5. Lower urinary tract symptoms 6. Aged 65-79 years
Provide patient population that should be included in the study
Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Prostatitis - Chronic Pelvic Pain Syndrome 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Electrical stimulation with non‐implanted devices for stress urinary incontinence in women
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Stress urinary incontinence 6. Mixed Incontinence 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Benign prostatic hyperplasia 4. Lower urinary tract symptoms 5. Aged 65-79 years
Provide patient population that should be included in the study
Desmopressin for treating nocturia in men
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Nocturia
Provide patient population that should be included in the study
Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants less than two years of age
1. Obstruction Of Pelviureteric Junction 2. Infant 1 to 23 mo 3. Birth to 1 mo
Provide patient population that should be included in the study
Antimicrobial therapy for chronic bacterial prostatitis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Prostatitis 5. Prostatitis Caused By Bacteria
Provide patient population that should be included in the study
Reconstructive surgery for treating pressure ulcers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Pressure ulcer 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Timing of antibiotic administration, wound debridement, and the stages of reconstructive surgery for open long bone fractures of the upper and lower limbs
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Open Fracture Of Bone 6. Aged 65-79 years
Provide patient population that should be included in the study
Reactive air surfaces for preventing pressure ulcers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Pressure ulcer 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Intracavity lavage and wound irrigation for prevention of surgical site infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Surgery 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Wound 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical phenytoin for treating pressure ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Pressure ulcer 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for treating gas gangrene
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Gas Gangrene 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Dressings and securement devices for central venous catheters (CVC)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Central Venous Catheterisation 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Devices and dressings to secure peripheral venous catheters to prevent complications
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Peripherally Inserted Central Catheterization 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Perioperative corticosteroids for preventing complications following facial plastic surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Facial plastic surgery 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Continuous versus interrupted skin sutures for non‐obstetric surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Surgery 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Pin site care for preventing infections associated with external bone fixators and pins
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infected External Fixator Pin 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Percutaneous Endoscopic Gastrostomy 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Interventions:
Skin care interventions in infants for preventing eczema and food allergy
1. Moisturizer application 2. Emollients And Protectives 3. Bathing Infant 4. Softeners, Emollients 5. Soap
Interventions:
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Antifungals For Systemic Use 2. Amphotericin 3. Azole antifungal 4. Oral 5. Nebulizer
Interventions:
Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Monoclonal Antibodies
Interventions:
Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children
1. Whole-cell pertussis vaccination
Interventions:
High versus low medium chain triglyceride content of formula for promoting short‐term growth of preterm infants
1. Enteral nutrition 2. Medium Chain Triglycerides 3. High Dose
Interventions:
Sublingual immunotherapy for asthma
1. Sublingual 2. Immunological Therapy
Interventions:
Dilute versus full‐strength formula in exclusively formula‐fed preterm or low birth weight infants
1. Water 2. Infant Formula
Interventions:
Probiotics for treating eczema
1. Probiotics
Interventions:
Infant formulas containing hydrolysed protein for prevention of allergic disease
1. Infant Formula 2. Protein Hydrolysates 3. Soy Milk 4. Cow's Milk
Interventions:
Oral and sublingual immunotherapy for egg allergy
1. Oral 2. Egg (chicken) Allergenic Extract 3. Sublingual
Interventions:
Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy
1. Breast Milk 2. Polyunsaturated Fatty Acid Supplementation
Interventions:
Specific allergen immunotherapy for the treatment of atopic eczema
1. Intradermal 2. Subcutaneous Immunotherapy 3. Oral 4. Subcutaneous 5. Allergen Immunotherapy 6. High Dose 7. Sublingual 8. Allergenic extract
Interventions:
Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion
1. Leucoreduced red blood cell transfusion
Interventions:
Immunotherapy (oral and sublingual) for food allergy to fruits
1. Oral 2. Sublingual 3. Immunological Therapy
Interventions:
Glycerin laxatives for prevention or treatment of feeding intolerance in very low birth weight infants
1. Glycerol
Interventions:
Maternal prenatal and/or postnatal n‐3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood
1. Polyunsaturated Fatty Acid Supplementation
Interventions:
H1‐antihistamines for chronic spontaneous urticaria
1. Antihistamines For Systemic Use
Interventions:
Omalizumab for asthma in adults and children
1. Omalizumab
Interventions:
Prebiotics in infants for prevention of allergy
1. Infant Formula 2. Breast Milk 3. Prebiotics
Interventions:
Lactase treated feeds to promote growth and feeding tolerance in preterm infants
1. Infant Formula 2. Tilactase 3. Breast Milk
Interventions:
Oral H1 antihistamines as monotherapy for eczema
1. Antihistamine 2. Oral
Interventions:
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta thalassaemia
1. Calcium Channel Blockers 2. Iron Chelating Agents
Interventions:
Topical repellents for malaria prevention
1. Mosquito Repellent
Interventions:
Interventions for chronic kidney disease in people with sickle cell disease
1. Red Blood Cell Transfusion 2. Hydroxyurea 3. Angiotensin-converting enzyme inhibitor
Interventions:
Rapamycin and rapalogs for tuberous sclerosis complex
1. Sirolimus
Interventions:
Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults
1. Antithymocyte Immunoglobulin 2. Prophylaxis 3. Usual Care
Interventions:
Treatment for osteoporosis in people with beta‐thalassaemia
1. Blood Transfusion
Interventions:
Treatment of dental and orthodontic complications in thalassaemia
1. Antibacterials For Systemic Use 2. Orthodontic Procedure 3. Analgesics 4. Prophylaxis 5. Orthodontic Appliance
Interventions:
Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias
1. Foetal haemoglobin inducers
Interventions:
Laser therapy for retinopathy in sickle cell disease
1. Laser Photocoagulation To Retina
Interventions:
Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease
1. Inhaled Bronchodilator Therapy
Interventions:
Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Usual Care 2. Extracorporeal Photopheresis
Interventions:
Hydroxyurea (hydroxycarbamide) for sickle cell disease
1. Hydroxyurea
Interventions:
Inhaled nitric oxide for treating pain crises in people with sickle cell disease
1. Nitric Oxide 2. Inhaled
Interventions:
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
1. Artesunate And Pyronaridine
Interventions:
Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis
1. Erythropoietin 2. IV Intravenous Injection 3. Iron Preparations 4. Oral
Interventions:
Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Usual Care 2. Extracorporeal Photopheresis
Interventions:
Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets
1. Indoor Residual Spraying 2. Mosquito Nets 3. Insecticides And Repellents
Interventions:
Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease
1. Angiotensin-converting enzyme inhibitor
Interventions:
Maternal and foetal outcomes following natural vaginal versus caesarean section (c‐section) delivery in women with bleeding disorders and carriers
1. Vaginal Delivery Of Fetus
Interventions:
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay‐Sachs disease
1. Preconception Genetic Risk Assessment 2. Community-Based 3. Healthcare Facility
Interventions:
Recombinant growth hormone therapy for X‐linked hypophosphatemia in children
1. Recombinant Human Growth Hormone 2. Usual Care
Interventions:
Mass drug administration for malaria
1. Mass drug administration
Interventions:
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
1. Galsulfase
Interventions:
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
1. Chimeric antigen receptor T-cell immunotherapy 2. Chemokine receptor antagonist 3. Drug Therapy
Interventions:
Rituximab for eradicating inhibitors in people with acquired haemophilia A
1. Cytotoxic agent 2. Rituximab 3. Corticosteroids - Systemic use
Interventions:
Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B
1. Prophylaxis 2. Clotting factor concentrate
Interventions:
Intermittent preventive treatment for malaria in infants
1. Preventative intervention 2. Intermittent Administration
Interventions:
Hematopoietic stem cell transplantation for people with β‐thalassaemia
1. Hemopoietic Stem Cell Transplant
Interventions:
Disease‐modifying treatments for primary autoimmune haemolytic anaemia
1. Mycophenolate Mofetil 2. Splenectomy 3. Plasma exchange 4. Corticosteroids - Opthamological and Otological 5. Rituximab 6. Cyclosporine 7. Alemtuzumab 8. Azathioprine 9. Immunoglobulins, Intravenous
Interventions:
Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease
1. Prophylaxis 2. Antibiotic Therapy
Interventions:
Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
1. Antimalarial 2. Atovaquone 3. Proguanil
Interventions:
Interventions for treating leg ulcers in people with sickle cell disease
1. Non-Pharmacological Interventions 2. Topical
Interventions:
Tyrosine supplementation for phenylketonuria
1. Tyrosine
Interventions:
Paediatric formulations of artemisinin‐based combination therapies for treating uncomplicated malaria in children
1. Artemisinin and derivatives combinations
Interventions:
Gene therapy for sickle cell disease
1. Gene Therapy 2. Usual Care
Interventions:
Phytomedicines (medicines derived from plants) for sickle cell disease
1. Phytotherapy
Interventions:
Rituximab for treating inhibitors in people with inherited severe hemophilia
1. Intravenous 2. Rituximab
Interventions:
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease
1. Preventive 2. Red Blood Cell Transfusion
Interventions:
Dietary interventions for phenylketonuria
1. Dietary Regime 2. Amino acid supplement
Interventions:
Interventions for mycosis fungoides
1. Systemic 2. Topical 3. Phototherapy Of Skin
Interventions:
Hematopoietic stem cell transplantation for people with sickle cell disease
1. Hemopoietic Stem Cell Transplant
Interventions:
Preoperative blood transfusions for sickle cell disease
1. Blood Transfusion 2. Preoperative
Interventions:
Interventions for treating intrahepatic cholestasis in people with sickle cell disease
1. Activated Charcoal 2. Rifampicin 3. Dexamethasone 4. Exchange Transfusion 5. Opiate antagonist 6. Guar gum 7. Liver transplant 8. Red Blood Cell Transfusion 9. Bile Acid Sequestrants 10. Sertraline
Interventions:
Growth hormone therapy for people with thalassaemia
1. Somatropin
Interventions:
Vitamin D supplementation for sickle cell disease
1. Oral 2. Vitamin D and analogues
Interventions:
Gene therapy for haemophilia
1. Gene Therapy 2. Usual Care
Interventions:
Interventions for preventing silent cerebral infarcts in people with sickle cell disease
1. Preventive 2. Hemopoietic Stem Cell Transplant 3. Hydroxyurea 4. Red Blood Cell Transfusion
Interventions:
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease
1. Transcutaneous Electrical Nerve Stimulation 2. Usual Care
Interventions:
Early erythropoiesis‐stimulating agents in preterm or low birth weight infants
1. Erythropoietin
Interventions:
Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants
1. Erythropoietin 2. Iron Preparations
Interventions:
Blood transfusions for treating acute chest syndrome in people with sickle cell disease
1. Blood Component Transfusion 2. Exchange Transfusion
Interventions:
Intravenous iron therapy for non‐anaemic, iron‐deficient adults
1. Intravenous Infusion Of Iron
Interventions:
Treatment of dental complications in sickle cell disease
1. Preventive 2. Analgesics 3. Comprehensive Orthodontic Treatment 4. Dental procedures
Interventions:
Treatment for avascular necrosis of bone in people with sickle cell disease
1. Bone Graft 2. Joint reconstruction 3. Osteotomy 4. Autogenous Vascularized Bone Graft 5. Physiotherapy 6. Electrical stimulation 7. Bisphosphonates 8. Restriction Of Movement 9. Stem Cell Transplantation 10. General Observation 11. Analgesics 12. Red Blood Cell Transfusion 13. Decompression Of Joint
Interventions:
Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non‐cardiac surgery or invasive procedures
1. Perioperative 2. Prophylaxis 3. Plasma transfusion
Interventions:
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis
1. Bortezomib 2. Lenalidomide 3. Thalidomide
Interventions:
Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults
1. Pharmacotherapy
Interventions:
Statins for children with familial hypercholesterolemia
1. Statins
Interventions:
Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease
1. Red Blood Cell Transfusion
Interventions:
Antibiotics for treating osteomyelitis in people with sickle cell disease
1. Antibiotic Therapy
Interventions:
Splenectomy for people with thalassaemia major or intermedia
1. Splenectomy
Interventions:
Magnesium for treating sickle cell disease
1. Intravenous 2. Magnesium
Interventions:
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions
1. Preventive 2. Antifibrinolytics
Interventions:
Hydroxyurea (hydroxycarbamide) for transfusion‐dependent β‐thalassaemia
1. Hydroxyurea
Interventions:
Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders
1. Desmopressin
Interventions:
Aerobic physical exercise for adult patients with haematological malignancies
1. Aerobic Exercise 2. Usual Care
Interventions:
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition
1. Prophylaxis 2. Mesenchymal stromal cells
Interventions:
Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer
1. Recommendation To Discontinue A Procedure 2. Following Protocol
Interventions:
Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia
1. Intravenous 2. Coagulation Factor Xiii 3. Prothrombin Complex Concentrate 4. Fibrinogen Concentrate
Interventions:
Vaccines for preventing invasive salmonella infections in people with sickle cell disease
1. Preventive 2. Salmonella Vaccination
Interventions:
Insecticide‐treated nets for preventing malaria
1. Mosquito Nets
Interventions:
Drugs for preventing red blood cell dehydration in people with sickle cell disease
1. Preventive
Interventions:
Prophylactic platelet transfusions prior to surgery for people with a low platelet count
1. Prophylaxis 2. Platelet transfusion 3. Platelet Concentrate, Pooling
Interventions:
Conjugate Haemophilus influenzae type b vaccines for sickle cell disease
1. Preventive 2. Haemophilus Influenzae Type B Vaccination
Interventions:
Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (non‐APL))
1. Chemotherapy 2. Tretinoin
Interventions:
Comparison of a therapeutic‐only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders
1. Intravenous 2. Platelet transfusion 3. Therapeutic Intent
Interventions:
Folate supplementation in people with sickle cell disease
1. Folic Acid Supplementation
Interventions:
Mosquito repellents for malaria prevention
1. Mosquito Repellent
Interventions:
Bisphosphonates in multiple myeloma: an updated network meta‐analysis
1. Bisphosphonates
Interventions:
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumours
1. Thrombolytic agent
Interventions:
Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease
1. Splenectomy 2. Preventive 3. Partial Splenectomy
Interventions:
Hematopoietic stem cell transplantation for Gaucher disease
1. Hemopoietic Stem Cell Transplant
Interventions:
Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn
1. Calcium 2. Intravenous 3. Prophylaxis
Interventions:
Thrombopoietin mimetics for patients with myelodysplastic syndromes
1. Thrombolytic agent
Interventions:
Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation
1. Preventive 2. Plasma transfusion
Interventions:
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
1. Recombinant Antihemophilic Factor VIII 2. Prophylaxis 3. Prothrombin Complex Concentrate
Interventions:
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis
1. Chemotherapy 2. Radiotherapy
Interventions:
Deferasirox for managing iron overload in people with thalassaemia
1. Deferasirox 2. Oral
Interventions:
Fluid replacement therapy for acute episodes of pain in people with sickle cell disease
1. Body Fluid Replacement
Interventions:
Pathogen‐reduced platelets for the prevention of bleeding
1. Platelet transfusion
Interventions:
Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
1. Escalated BEACOPP 2. Radiotherapy
Interventions:
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
1. Chemotherapy
Interventions:
Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients
1. Unfractionated Heparin Therapy
Interventions:
Exercise for haemophilia
1. Physical therapy exercises
Interventions:
Antibiotics for treating community‐acquired pneumonia in people with sickle cell disease
1. Antibiotic Therapy
Interventions:
Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias
1. Hydroxyurea
Interventions:
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review
1. Romiplostim 2. Desmopressin 3. Eltrombopag 4. Tranexamic Acid
Interventions:
Bisphosphonate therapy for osteogenesis imperfecta
1. Bisphosphonates
Interventions:
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications
1. Education 2. Group Education
Interventions:
Bortezomib for the treatment of multiple myeloma
1. Bortezomib
Interventions:
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
1. Preventive 2. Tranexamic Acid 3. Aminocaproic Acid
Interventions:
Subsidising artemisinin‐based combination therapy in the private retail sector
1. Artemisinin and derivatives combinations
Interventions:
Oral iron supplements for children in malaria‐endemic areas
1. Folic Acid 2. Antimalarial 3. Iron Preparations
Interventions:
Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
1. Chemotherapy 2. Granulocyte-macrophage Colony Stimulating Factors 3. Granulocyte Colony Stimulating Factors 4. Erythropoietin Therapy
Interventions:
Piracetam for reducing the incidence of painful sickle cell disease crises
1. Piracetam 2. Oral
Interventions:
Meditation for adults with haematological malignancies
1. Transcendental Meditation Therapy 2. Usual Care
Interventions:
Washed versus unwashed red blood cells for transfusion for the prevention of morbidity and mortality in preterm infants
1. Washed red blood cell transfusion 2. Red Blood Cell Transfusion
Interventions:
Antibody therapies for lymphoma in children
1. Monoclonal Antibodies 2. Usual Care
Interventions:
Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
1. Colony Stimulating Factors
Interventions:
Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease
1. Subcutaneous 2. Low Molecular Weight Heparin
Interventions:
Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors
1. Factor Viia
Interventions:
Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia
1. Platelet transfusion
Interventions:
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Transfusion Using High Hemoglobin Threshold 2. Prophylaxis 3. Platelet transfusion 4. Platelet Concentrate, Pooling 5. Transfusion Using Low Hemoglobin Threshold
Interventions:
Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission
1. Chemotherapy 2. Interleukin-2 Therapy
Interventions:
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Low Dose 2. Platelet transfusion 3. High Dose
Interventions:
Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma
1. Colony Stimulating Factors 2. Hemopoietic Stem Cell Transplant 3. Plerixafor
Interventions:
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders
1. Allogeneic Blood Bag 2. Red Blood Cell Transfusion
Interventions:
A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Prophylaxis 2. Platelet transfusion
Interventions:
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia
1. Idarubicin
Interventions:
Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell transplantation
1. Administration Of Prophylactic Medication
Interventions:
Psychological therapies for sickle cell disease and pain
1. Psychodynamic Psychotherapy 2. Behavioral Therapy 3. Cognitive Behavioral Therapy 4. Patient Education
Interventions:
Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis
1. Ruxolitinib
Interventions:
Sapropterin dihydrochloride for phenylketonuria
1. Sapropterin 2. Oral
Interventions:
Enzyme replacement and substrate reduction therapy for Gaucher disease
1. Enzymes for alimentary tract and metabolism 2. Miglustat
Interventions:
Protein substitute for children and adults with phenylketonuria
1. Protein Supplements
Interventions:
Artemisinin‐naphthoquine for treating uncomplicated Plasmodium falciparum malaria
1. Artemisinin 2. Naphthoquine
Interventions:
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery
1. Preventive 2. Hemostatic agent 3. Other Hematological Agents
Interventions:
Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma
1. Positron Emission Tomography 2. Diagnostic Intent
Interventions:
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
1. Eculizumab
Interventions:
Deferasirox for managing iron overload in people with myelodysplastic syndrome
1. Deferasirox
Interventions:
Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
1. Antimalarial
Interventions:
Interventions for treating acute bleeding episodes in people with acquired hemophilia A
1. Activated prothrombin complex concentrate 2. 1-desamino-8-D-arginine-vasopressin 3. Recombinant FVIIa
Interventions:
Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic hematopoietic stem cell transplantation
1. Mycophenolate Mofetil
Interventions:
The role of additional radiotherapy for primary central nervous system lymphoma
1. Chemotherapy 2. Radiotherapy
Interventions:
Deferasirox for managing transfusional iron overload in people with sickle cell disease
1. Deferasirox
Interventions:
Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria
1. Dihydroartemisinin–piperaquine
Interventions:
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
1. Primaquine 2. Chloroquine
Interventions:
Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria
1. Artemisinin and derivatives combinations
Interventions:
Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment
1. Surgical Removal
Interventions:
Hyperbaric oxygen therapy for late radiation tissue injury
1. Hyperbaric Oxygen Therapy
Interventions:
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
1. Chemotherapy 2. Immunological Therapy 3. Bevacizumab
Interventions:
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
1. Chemotherapy 2. Doxorubicin Hydrochloride Liposome 3. Platinum Combination Chemotherapy
Interventions:
Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy
1. Local Excision
Interventions:
Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery
1. Prehabilitation
Interventions:
First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis
1. First Line Treatment
Interventions:
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
1. Chemotherapy 2. Angiogenesis inhibitor
Interventions:
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk
1. Screening Mammography 2. Breast ultrasonography
Interventions:
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer
1. Lifestyle education 2. Serotonin Antagonists 3. Orlistat 4. Recommendation To Stop Behavior 5. Centrally acting appetite suppressant
Interventions:
Skin‐sparing mastectomy for the treatment of breast cancer
1. Skin Sparing Mastectomy
Interventions:
Exercise interventions for adults with cancer receiving radiation therapy alone
1. Exercise therapy
Interventions:
Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
1. Radiotherapy
Interventions:
Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery
1. Mechanical bowel preparation 2. Antibiotic Therapy
Interventions:
Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer
1. Corticosteroids
Interventions:
Neoadjuvant treatment for stage III and IV cutaneous melanoma
1. Neo-adjuvant 2. Chemotherapy 3. Drug Therapy 4. Topical 5. Systemic 6. Targeted Therapy 7. Radiotherapy 8. Immunological Therapy
Interventions:
Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer
1. Chemotherapy 2. Mushroom preperation 3. Radiotherapy
Interventions:
Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer
1. Preventive 2. Antifungals For Systemic Use
Interventions:
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation
1. Preventive 2. Non-Pharmacological Interventions
Interventions:
Preoperative exercise training for people with non‐small cell lung cancer
1. Exercise therapy 2. Preoperative
Interventions:
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines
1. Anthracycline 2. Dexrazoxane
Interventions:
Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer
1. Hysterectomy
Interventions:
Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care
1. Methylnaltrexone 2. Mu-opioid Receptor Antagonist 3. Naloxone
Interventions:
Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
1. Surgery
Interventions:
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer
1. Radiochemotherapy: To Stop Spread 2. Radical Hysterectomy 3. Neo-adjuvant 4. Chemotherapy 5. Hysterectomy 6. Radiotherapy
Interventions:
Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality
1. Lose dose computed tomography 2. Cancer screening
Interventions:
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
1. Taxanes
Interventions:
Oxycodone for cancer‐related pain
1. Oxycodone
Interventions:
Perioperative enhanced recovery programmes for women with gynaecological cancers
1. Enhanced Recovery After Surgery
Interventions:
Gases for establishing pneumoperitoneum during laparoscopic abdominal surgery
1. Therapeutic Insufflation 2. Medical Gases 3. Surgical Pneumoperitoneum
Interventions:
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
1. Paclitaxel 2. Carboplatin
Interventions:
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
1. Chemotherapy 2. DNA-repair Pathway Inhibitor
Interventions:
Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy
1. Antecolic reconstruction
Interventions:
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. Food
Interventions:
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
1. Anaplastic lymphoma kinase inhibitors 2. Therapeutic Intent 3. Targeted Therapy
Interventions:
Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers
1. Early Treatment 2. Specialist Palliative Care Treatment
Interventions:
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
1. Chemotherapy
Interventions:
Prophylactic abdominal drainage for pancreatic surgery
1. Abdominal Drain
Interventions:
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent
1. Cancer immunotherapy 2. Radical radiotherapy
Interventions:
Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer
1. Transurethral resection of bladder tumour 2. Blue light cytoscopy 3. Hexyl 5-aminolevulinate 4. Aminolevulinic Acid
Interventions:
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
1. 5-HT3 Receptor Antagonist 2. Corticosteroids 3. Neurokinin 1 receptor antagonist
Interventions:
Perioperative systemic nonsteroidal anti‐inflammatory drugs (NSAIDs) in women undergoing breast surgery
1. Non-steroidal Anti-inflammatory Drug
Interventions:
Music interventions for improving psychological and physical outcomes in people with cancer
1. Music Therapy
Interventions:
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
1. Direct acting anticoagulant 2. Vitamin K Antagonists
Interventions:
Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer
1. Preventive 2. Heparin Irrigation Solution 3. Antibiotic Prophylaxis
Interventions:
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
1. Indirect acting anticoagulant 2. Antiplatelet agent 3. Anticoagulant therapy
Interventions:
School‐based physical activity programs for promoting physical activity and fitness in children and adolescents aged 6 to 18
1. Referral To Physical Activity Program 2. School
Interventions:
Roux‐en‐Y versus Billroth‐I reconstruction after distal gastrectomy for gastric cancer
1. Roux-en-y gastric bypass
Interventions:
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma
1. Chemotherapy 2. Adjuvant
Interventions:
Interventions targeted at women to encourage the uptake of cervical screening
1. Educational Material 2. Risk Assessment 3. Counseling 4. Screening Procedure
Interventions:
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma
1. Chemotherapy 2. Transplantation Of Autologous Hematopoietic Stem Cell 3. High Dose
Interventions:
Partial breast irradiation versus whole breast radiotherapy for early breast cancer
1. Partial Breast Radiotherapy
Interventions:
Hydromorphone for cancer pain
1. Hydromorphone
Interventions:
Degarelix for treating advanced hormone‐sensitive prostate cancer
1. Degarelix
Interventions:
Physical therapy interventions, other than general physical exercise interventions, in children and adolescents before, during and following treatment for cancer
1. Physiotherapy
Interventions:
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer
1. Chemotherapy 2. Adjuvant 3. Interventional Debulking Surgery
Interventions:
Protons versus photons for the treatment of chordoma
1. Proton teletherapy 2. Neutron Teletherapy 3. Radiotherapy
Interventions:
Intravesical gemcitabine for non‐muscle invasive bladder cancer
1. Gemcitabine 2. Intravesical
Interventions:
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
1. Immune checkpoint inhibitors
Interventions:
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
1. Chemotherapy 2. Poly ADP-Ribose Ploymerase Inhibitors
Interventions:
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
1. Cytotoxic agent 2. Chemotherapy
Interventions:
Exercise for cancer cachexia in adults
1. Active Exercise 2. Physical therapy exercises
Interventions:
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
1. Chemotherapy 2. Surgery 3. Targeted Therapy 4. Radiotherapy 5. Angiogenesis inhibitor
Interventions:
Paravertebral anaesthesia with or without sedation versus general anaesthesia for women undergoing breast cancer surgery
1. Paravertebral Anesthesia
Interventions:
Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis
1. Experimental Therapeutic Procedure 2. Chemotherapy 3. Surgery 4. Radiotherapy
Interventions:
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
1. Surveillance 2. Levonorgestrel-releasing Intrauterine System
Interventions:
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
1. Prednisone 2. Androgen Deprivation Therapy 3. Abiraterone Acetate
Interventions:
Body weight management in overweight and obese breast cancer survivors
1. Weight Management Programme
Interventions:
Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
1. Other Drugs Affecting Bone Structure And Mineralization 2. Bisphosphonates
Interventions:
Platinum‐containing regimens for triple‐negative metastatic breast cancer
1. Chemotherapy 2. Platinum
Interventions:
Targeted therapy for metastatic renal cell carcinoma
1. Targeted Therapy
Interventions:
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
1. Prophylaxis 2. Asparaginase
Interventions:
The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with advanced illness and their caregivers
1. Specialist Palliative Care Treatment - Inpatient
Interventions:
Retzius‐sparing versus standard robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
1. Laparoscopic Radical Prostatectomy Using Robotic Assistance
Interventions:
Helicobacter pylori eradication for the prevention of gastric neoplasia
1. Helicobacter Eradication Therapy
Interventions:
Radical prostatectomy versus deferred treatment for localised prostate cancer
1. Radical Prostatectomy
Interventions:
Telephone interventions for symptom management in adults with cancer
1. Telephone delivered intervention
Interventions:
Surgery versus radical endotherapies for early cancer and high‐grade dysplasia in Barrett's oesophagus
1. Endotherapy 2. Curative
Interventions:
External beam radiation dose escalation for high grade glioma
1. Hypofractionated Radiation Therapy 2. Accelerated Radiotherapy 3. Hyperfractionated Radiotherapy 4. Fractionated Dose Stereotactic Radiosurgery Using Linear Accelerator System
Interventions:
Physical activity interventions for disease‐related physical and mental health during and following treatment in people with non‐advanced colorectal cancer
1. Exercise therapy 2. Physical therapy exercises 3. Usual Care
Interventions:
Interventions for the management of malignant pleural effusions: a network meta‐analysis
1. Pleural Catheter 2. Chlormethine 3. Cryptosporidium Parvum 4. Doxorubicin 5. Pleural Poudrage 6. Tetracycline 7. Bleomycin 8. Thiotepa 9. Doxycycline 10. Talc Pleurodesis 11. Intrapleural 12. Interferon 13. Mepacrine 14. Mitoxantrone 15. Iodine
Interventions:
Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer
1. Education About Health Seeking Behaviour
Interventions:
Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer
1. Ovarian function suppression
Interventions:
Drugs for preventing lung cancer in healthy people
1. Preventive 2. Mineral Supplements 3. Vitamins
Interventions:
Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. Exercise therapy
Interventions:
Hormone replacement therapy after surgery for epithelial ovarian cancer
1. Hormone Replacement Therapy
Interventions:
Drug therapy for delirium in terminally ill adults
1. Pharmacotherapy
Interventions:
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
1. Preventive 2. Intravenous Infusion 3. Platinum Compounds
Interventions:
Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas
1. Postoperative Course Of Radiotherapy 2. Early Treatment
Interventions:
Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
1. Chemotherapy 2. Cisplatin
Interventions:
Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer
1. Instillation Of Bcg Into The Bladder 2. Intravesical
Interventions:
Interval brain imaging for adults with cerebral glioma
1. Diagnostic imaging 2. Continuous Administration
Interventions:
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
1. Human Papillomavirus Vaccine
Interventions:
Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors
1. Monitoring Of Patient With Cancer 2. Follow-up Consultation 3. Specialized Physician 4. Signs And Symptoms Education 5. Clinical examination 6. Diagnostic Procedure
Interventions:
Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
1. Perioperative 2. Antibiotic Prophylaxis 3. Preoperative
Interventions:
Follow‐up strategies for patients treated for non‐metastatic colorectal cancer
1. Postoperative Follow-up Visit
Interventions:
Taxanes for adjuvant treatment of early breast cancer
1. Chemotherapy 2. Taxanes
Interventions:
Hypofractionation for clinically localized prostate cancer
1. Hypofractionated Radiation Therapy